Lucid Diagnostics Inc.
Lucid Diagnostics Inc.
Your view on LUCD
Overview
What the company does, where it operates, and who runs it.
About Lucid Diagnostics Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Lishan Aklog
- Headquarters
- One Grand Central Place, New York City, NY, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Lishan Aklog
- Headquarters
- One Grand Central Place, New York City, NY, US
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company.
The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Lucid Diagnostics Inc., and the rating behind it. LUCD last traded at $0.78; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Lucid Diagnostics Inc.. Starting points for Lucid Diagnostics Inc.: EPS -$0.29, beta 1.10 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Lucid Diagnostics Inc.. Lucid Diagnostics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Lucid Diagnostics Inc.. Trailing twelve-month EPS for Lucid Diagnostics Inc. stands at -$0.29. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Lucid Diagnostics Inc.. Lucid Diagnostics Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Lucid Diagnostics Inc. valued side by side against its closest peers. Lucid Diagnostics Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Lucid Diagnostics Inc., and how their positions are changing. At a $149.4M market value, institutional positions materially move Lucid Diagnostics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Lucid Diagnostics Inc. executives and directors. Shares of Lucid Diagnostics Inc. have traded between $0.75 and $1.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Lucid Diagnostics Inc.. Lucid Diagnostics Inc. is a $149.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Lucid Diagnostics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Lucid Diagnostics Inc.. Coverage tracks Lucid Diagnostics Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.